Silo Pharma (NASDAQ:SILO – Get Free Report) and Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.
Earnings and Valuation
This table compares Silo Pharma and Chugai Pharmaceutical”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Silo Pharma | $70,000.00 | 48.27 | -$4.23 million | ($4.36) | -0.49 |
| Chugai Pharmaceutical | $8.41 billion | 8.03 | $2.91 billion | $0.92 | 22.30 |
Profitability
This table compares Silo Pharma and Chugai Pharmaceutical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Silo Pharma | -6,726.39% | -81.75% | -66.35% |
| Chugai Pharmaceutical | 35.09% | 23.76% | 19.92% |
Analyst Ratings
This is a breakdown of current ratings for Silo Pharma and Chugai Pharmaceutical, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Silo Pharma | 1 | 0 | 0 | 0 | 1.00 |
| Chugai Pharmaceutical | 0 | 3 | 1 | 1 | 2.60 |
Volatility and Risk
Silo Pharma has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Chugai Pharmaceutical has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500.
Institutional and Insider Ownership
5.6% of Silo Pharma shares are held by institutional investors. Comparatively, 0.0% of Chugai Pharmaceutical shares are held by institutional investors. 3.6% of Silo Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Chugai Pharmaceutical beats Silo Pharma on 10 of the 14 factors compared between the two stocks.
About Silo Pharma
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
About Chugai Pharmaceutical
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
Receive News & Ratings for Silo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
